S-17092 Explained
S-17092 is a drug which acts as a selective inhibitor of the enzyme prolyl endopeptidase.[1] This enzyme is involved in the metabolic breakdown of a number of neuropeptide neurotransmitters in the brain,[2] [3] and so inhibiting the action of the enzyme increases the activity of these neuropeptides. This produces nootropic effects which make S-17092 a promising and novel treatment for neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease.[4] [5]
See also
Notes and References
- Barelli H, Petit A, Hirsch E, Wilk S, De Nanteuil G, Morain P, Checler F . S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase . Biochemical and Biophysical Research Communications . 257 . 3 . 657–61 . April 1999 . 10208839 . 10.1006/bbrc.1999.0366 .
- Bellemère G, Morain P, Vaudry H, Jégou S . Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain . Journal of Neurochemistry . 84 . 5 . 919–29 . March 2003 . 12603817 . 10.1046/j.1471-4159.2003.01536.x . 24773419 .
- Bellemère G, Vaudry H, Morain P, Jégou S . Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain . Journal of Neuroendocrinology . 17 . 5 . 306–13 . May 2005 . 15869566 . 10.1111/j.1365-2826.2005.01308.x . 9129184 .
- Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin JL, Guez D, Boyer PA . S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies . CNS Drug Reviews . 8 . 1 . 31–52 . 12070525 . 6741683 . 2002 . 10.1111/j.1527-3458.2002.tb00214.x .
- Morain P, Boeijinga PH, Demazières A, De Nanteuil G, Luthringer R . Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers . Neuropsychobiology . 55 . 3–4 . 176–83 . 17700042 . 10.1159/000107070 . 2007 . 27856130 .